Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma.

Chen KD, Wang CC, Tsai MC, Wu CH, Yang HJ, Chen LY, Nakano T, Goto S, Huang KT, Hu TH, Chen CL, Lin CC.

Cell Death Dis. 2014 May 22;5:e1244. doi: 10.1038/cddis.2014.212.

2.

Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.

Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, Chen LY, Hu TH, Goto S, Nakano T, Dorling A, McVey JH, Chen CL, Lin CC.

Cell Death Discov. 2015 Nov 30;1:15051. doi: 10.1038/cddiscovery.2015.51. eCollection 2015.

3.

mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.

Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, Liu Z, Sun Q, Peng H, Chen R, Jing Y, Yang H, Mao Y, Zhang H.

Gastroenterology. 2015 Sep;149(3):741-52.e14. doi: 10.1053/j.gastro.2015.05.005. Epub 2015 May 14.

PMID:
25980751
4.

Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.

Carcinogenesis. 2013 Jun;34(6):1331-42. doi: 10.1093/carcin/bgt060. Epub 2013 Feb 7.

PMID:
23393227
5.

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.

Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.

6.

MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.

He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.

Oncotarget. 2015 Oct 6;6(30):28867-81. doi: 10.18632/oncotarget.4814.

7.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

8.

[IL-12 induces autophagy via AKT/mTOR/STAT3 signaling pathway in human hepatoma cells].

Liu C, Xie C, Lin Y, Wu B, Wang Q, Li Z, Tu Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Jul;32(7):870-5. Chinese.

PMID:
27363263
9.

Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.

Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY.

Gastroenterology. 2015 Oct;149(4):1068-81.e5. doi: 10.1053/j.gastro.2015.06.010. Epub 2015 Jun 20.

PMID:
26099525
10.

The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.

Wang C, Wang X, Su Z, Fei H, Liu X, Pan Q.

Oncol Rep. 2015 Oct;34(4):1708-16. doi: 10.3892/or.2015.4146. Epub 2015 Jul 23.

PMID:
26239364
11.

Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2.

Larsen KS, Ostergaard H, Olsen OH, Bjelke JR, Ruf W, Petersen LC.

J Biol Chem. 2010 Jun 25;285(26):19959-66. doi: 10.1074/jbc.M110.101030. Epub 2010 Apr 13.

12.

Inhibition of autophagic flux by salinomycin results in anti-cancer effect in hepatocellular carcinoma cells.

Klose J, Stankov MV, Kleine M, Ramackers W, Panayotova-Dimitrova D, Jäger MD, Klempnauer J, Winkler M, Bektas H, Behrens GM, Vondran FW.

PLoS One. 2014 May 9;9(5):e95970. doi: 10.1371/journal.pone.0095970. eCollection 2014.

13.

Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.

Ma L, Wang X, Jia T, Wei W, Chua MS, So S.

Oncotarget. 2015 Sep 22;6(28):25390-401. doi: 10.18632/oncotarget.4455.

14.

Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.

Chen YJ, Chi CW, Su WC, Huang HL.

Oncotarget. 2014 Jul 15;5(13):4845-54.

16.

Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling.

Zou M, Lu N, Hu C, Liu W, Sun Y, Wang X, You Q, Gu C, Xi T, Guo Q.

Cell Signal. 2012 Aug;24(8):1722-32. doi: 10.1016/j.cellsig.2012.04.009. Epub 2012 Apr 25.

PMID:
22560876
17.

Coagulation factor VII and malignant progression of hepatocellular carcinoma.

Chen KD, Huang KT, Tsai MC, Wu CH, Kuo IY, Chen LY, Hu TH, Chen CL, Lin CC.

Cell Death Dis. 2016 Feb 25;7:e2110. doi: 10.1038/cddis.2015.395. No abstract available.

18.

RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.

Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW.

Oncotarget. 2014 Jul 15;5(13):4909-19.

19.

MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R.

Ge YY, Shi Q, Zheng ZY, Gong J, Zeng C, Yang J, Zhuang SM.

Oncotarget. 2014 Aug 15;5(15):6218-28.

20.

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.

Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW.

Oncotarget. 2015 Nov 10;6(35):37200-15. doi: 10.18632/oncotarget.5808.

Supplemental Content

Support Center